Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Continuation of clinical trials demonstrates commitment to developing treatments for thyroid eye disease.
- Advancement of a novel preclinical portfolio indicates potential for future growth and expansion into treating autoimmune diseases.
- Successful private placement of $185 million ensures sufficient funding for pipeline development and operations until 2026.
- None.
- THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 -
- Timing for the selection of lead subcutaneous TED program is on track for the end of 2023 -
- Advancing recently announced novel preclinical portfolio of potentially best-in-class neonatal Fc receptor (FcRn) inhibitors with the broad potential to treat autoimmune diseases -
- Announced the appointment of Stephen Mahoney as President and Chief Executive Officer -
- Closed a private placement of approximately
“We are focused on driving execution of our potentially best-in-class anti-IGF-1R therapies to reach meaningful clinical readouts in our intravenous and subcutaneous TED franchise,” said Steve Mahoney, President and CEO of Viridian Therapeutics. “We recently reiterated our expectations for our timelines and unveiled our novel anti-FcRn portfolio for autoimmune diseases with our first investigational new drug (IND) submission for this program planned by year end 2024. Finally, our recent closing of a private placement for approximately
Program Highlights
Thyroid eye disease (TED)
Intravenous TED Program: VRDN-001
Viridian’s lead product candidate, VRDN-001, is a monoclonal antibody that acts as a full antagonist of insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for TED that has a current US annual market opportunity of approximately
- The ongoing THRIVE Phase 3 clinical trial of VRDN-001 in patients with active TED continues to enroll patients with topline results expected in mid-2024.
- THRIVE-2, a Phase 3 clinical trial of VRDN-001 in patients with chronic TED, is active and enrolling patients with topline results anticipated by year end 2024.
- THRIVE and THRIVE-2 are each designed to compare a five-dose treatment arm of VRDN-001, dosed three weeks apart, to placebo. This five-dose VRDN-001 regimen features fewer infusions and a shorter time per infusion compared to the currently marketed IGF-1R inhibitor.
- In a Phase 1/2 clinical trial, intravenous VRDN-001 was shown to improve the signs and symptoms of TED at six weeks in patients with active and chronic disease after receiving two infusions of VRDN-001 in all dose cohorts and was generally well-tolerated.
Subcutaneous TED Programs: VRDN-001, VRDN-002, and VRDN-003
Subcutaneous VRDN-001 is the same monoclonal antibody as the intravenous program formulated for subcutaneous delivery. VRDN-002 constitutes a different novel monoclonal antibody targeting IGF-1R and is engineered to have an extended half-life to allow for less frequent dosing. VRDN-003 combines the same binding domain from VRDN-001 with the same engineered extended half-life of VRDN-002. The company is conducting Phase 1 clinical trials in healthy volunteers with subcutaneous VRDN-001, VRDN-002, and VRDN-003 to evaluate each program’s pharmacokinetics and safety.
- Enrollment has been completed in the Phase 1 clinical trials to evaluate the pharmacokinetics and safety of subcutaneous VRDN-001, VRDN-002, and VRDN-003 in healthy volunteers, and data are expected in the fourth quarter of 2023.
- Viridian is on track to select its lead subcutaneous program by year end 2023 and plans to disclose available subcutaneous data for VRDN-001, VRDN-002 and VRDN-003 supporting this program selection for a potentially best-in-class anti-IGF-1R product candidate.
- Viridian entered into a subcutaneous autoinjector supply agreement with Ypsomed in October 2023 to support its development of convenient subcutaneous therapies for the treatment of TED.
Autoimmune Diseases
Next Generation FcRn Portfolio: VRDN-006 and VRDN-008
Viridian is developing a portfolio of engineered FcRn inhibitors. FcRn inhibition has the potential to treat a broad array of autoimmune diseases, representing a significant commercial opportunity. VRDN-006 is a highly selective Fc fragment. VRDN-008 is a novel, first-in-class FcRn inhibitor that aims to pair immunoglobulin G (IgG) suppression with extended half-life technology.
- VRDN-006 showed specificity for blocking FcRn-IgG interactions in non-human primates while showing no increases in albumin or low-density lipoprotein (LDL) levels.
- VRDN-008, with its extended half-life, has the potential to more deeply and durably suppress IgG as compared to existing anti-FcRn therapies and pipeline candidates.
- The company is designing both VRDN-006 and VRDN-008 to be convenient, self-administered, subcutaneous products.
- Viridian plans to file an IND for VRDN-006 by year end 2024 and anticipates sharing additional details on both programs in 2024.
Corporate Highlights
- In October 2023, the Company appointed Stephen Mahoney as President and Chief Executive Officer and a member of the Board of Directors. Mr. Mahoney brings more than two decades of experience in the biopharmaceutical industry where he has held a number of strategic, operational, financial, business development, and legal roles with regional and global responsibilities.
- In October 2023, along with Mr. Mahoney’s appointment, the company also hired Thomas Beetham as Chief Operating Officer, and Shan Wu, Ph.D., as Chief Business Officer. Each has worked with Mr. Mahoney in prior companies and will strengthen Viridian’s management team.
Financial Results
-
Cash Position: Cash, cash equivalents, and short-term investments were
$313 million $334.3 million $185 million -
R&D Expenses: Research and development expenses were
$30.4 million $22.1 million -
G&A Expenses: General and administrative expenses were
$20.9 million $8.9 million -
Net Loss: The company’s net loss was
$47.7 million $28.9 million - Shares outstanding: Following the closing of its private placement financings, as of the date hereof, Viridian had approximately 73,650,891 shares of common stock outstanding on an as-converted basis, which included 52,586,039 shares of common stock and an aggregate of approximately 21,064,852 shares of common stock issuable upon the conversion of 172,435 and 143,522 shares of Series A and Series B preferred stock, respectively.
Viridian will not be hosting a conference call to discuss its third quarter financial results.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Simultaneously, the company is developing its subcutaneous program strategy with the goal of providing a potentially more conveniently administered therapy to patients with TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is also developing additional preclinical assets in autoimmune and rare diseases.
Viridian is based in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding our expectations, strategies, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the potential efficacy and safety of VRDN-001, VRDN-002, and VRDN-003 for the treatment of Thyroid Eye Disease (TED); the potential for VRDN-006 and VRDN-008; the relationship between the results from the positive data from the ongoing Phase 1/2 clinical trial of VRDN-001 in patients with chronic TED and the results of ongoing or future clinical trials; the timing, progress and plans for our ongoing or future research, pre-clinical and clinical development programs; trial protocols for ongoing clinical trials; expectations regarding the timing for IND filings; expectations regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, including VRDN-001, VRDN-002, and VRDN-003; manufacturing risks; our plan regarding selection of a lead SC program candidate; competition from other therapies or products; estimates of market size; other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; our financial position and its projected cash runway; our future operating results and financial performance; the clinical utility of our therapeutic candidates and our intellectual property position; the timing of pre-clinical and clinical trial activities and reporting results from same, including those risks set forth under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 13, 2023 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| (amounts in thousands, except share and per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended September 30, |
||||||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||||||
| Revenue: | |||||||||||||||
| Collaboration Revenue - related party | $ |
72 |
|
$ |
1,195 |
|
$ |
242 |
|
$ |
1,667 |
|
|||
| Total revenue |
|
72 |
|
|
1,195 |
|
|
242 |
|
|
1,667 |
|
|||
| Operating Expenses: | |||||||||||||||
| Research and development |
|
30,385 |
|
|
22,119 |
|
|
121,208 |
|
|
61,577 |
|
|||
| General and administrative |
|
20,911 |
|
|
8,861 |
|
|
62,006 |
|
|
25,328 |
|
|||
| Total operating expenses |
|
51,296 |
|
|
30,980 |
|
|
183,214 |
|
|
86,905 |
|
|||
| Loss from operations |
|
(51,224 |
) |
|
(29,785 |
) |
|
(182,972 |
) |
|
(85,238 |
) |
|||
| Other income | |||||||||||||||
| Interest and other income |
|
4,164 |
|
|
1,044 |
|
|
13,029 |
|
|
1,467 |
|
|||
| Interest and other expense |
|
(600 |
) |
|
(164 |
) |
|
(931 |
) |
|
(318 |
) |
|||
| Net loss |
|
(47,660 |
) |
|
(28,905 |
) |
|
(170,874 |
) |
|
(84,089 |
) |
|||
| Change in unrealized gain (loss) on investments |
|
109 |
|
|
137 |
|
|
326 |
|
|
(783 |
) |
|||
| Comprehensive loss | $ |
(47,551 |
) |
$ |
(28,768 |
) |
$ |
(170,548 |
) |
$ |
(84,872 |
) |
|||
| Net loss | $ |
(47,660 |
) |
$ |
(28,905 |
) |
$ |
(170,874 |
) |
$ |
(84,089 |
) |
|||
| Net loss per share, basic and diluted | $ |
(1.09 |
) |
$ |
(0.86 |
) |
$ |
(3.97 |
) |
$ |
(2.88 |
) |
|||
| Weighted-average shares used to compute basic and diluted loss per share |
|
43,654,577 |
|
|
33,742,076 |
|
|
43,057,658 |
|
|
29,238,247 |
|
|||
| Viridian Therapeutics, Inc. | |||||
| Selected Financial Information | |||||
| Condensed Condolidated Balance Sheets | |||||
| (amounts in thousands) | |||||
| (unaudited) | |||||
| September 30, | December 31, | ||||
2023 |
2022 |
||||
| Cash, cash equivalents and short-term investments | $ |
313,007 |
$ |
424,550 |
|
| Other assets |
|
15,750 |
|
10,541 |
|
| Total assets | $ |
328,757 |
$ |
435,091 |
|
| Total liabilities |
|
45,181 |
|
40,027 |
|
| Total stockholders’ equity |
|
283,576 |
|
395,064 |
|
| Total liabilities and stockholders’ equity | $ |
328,757 |
$ |
435,091 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20231113537474/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
What are the timelines for the THRIVE and THRIVE-2 clinical trials?
What is the purpose of the private placement of $185 million?
Who was appointed as President and CEO of Viridian Therapeutics?
What is the cash position of Viridian Therapeutics as of September 30, 2023?
What are the R&D expenses for the third quarter of 2023?
How many shares of common stock does Viridian Therapeutics have outstanding?
